Fig. 3: HDAC1 poses steric hindrance for the interaction between GABPA and Sp1.
From: Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAFV600E-driven human cancers
a Co-IP assay of whole-cell lysates derived from the indicated cells knocking down BRAF and control cells to validate the interaction between Sp1 and HDAC1. b ChIP-qPCR assay was performed to evaluate the effect of inhibition of BRAFV600E-mediated ERK activation on the binding of HDAC1 to TERT promoter in the indicated cells knocking down BRAF and control cells. c Co-IP assay was similarly performed in the indicated cells knocking down BRAF and control cells to validate the interaction between Sp1 and GABPA. d Western blot analysis was performed to determine the effect of HDAC1 knockdown on the expression and GABPA and Sp1 in the indicated cells. e Co-IP assay was performed to determine the effect of HDAC1 knockdown on the interaction between Sp1 and GABPA. Data were shown as mean ± SD. **P < 0.01; ***P < 0.001.
